dextroamphetamine has been researched along with Chronic Disease in 24 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of intratarsal triamcinolone acetonide (TA) injection versus dexamethasone ointment in the treatment of refractory chronic tropical endemic limboconjunctivitis (TELC)." | 9.16 | [Intratarsal triamcinolone acetonide injection for treatment of refractory chronic tropical endemic limboconjunctivitis (TELC): experience at Aristide-Le-Dantec university hospital in Dakar]. ( Ba, EH; Ka, AM; Ndiaye, MR; Ndoye Roth, PA; Ngatcho Hemo, J; Sow, AS; Wade, A; Wane Khouma, AM, 2012) |
| "Twenty-one patients with chronic schizophrenia who were hospitalized on a research ward received a single oral dose of dextroamphetamine (0." | 9.07 | Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. ( Bigelow, LB; Daniel, DG; Goldberg, TE; Kleinman, JE; Weinberger, DR, 1991) |
| "To present two other dermatologic conditions related to a disorder of sympathetic nervous system hypofunction common in women that respond to treatment with dextroamphetamine sulfate--chronic eczema and keratosis pilaris." | 7.80 | Complete eradication of chronic long standing eczema and keratosis pilaris following treatment with dextroamphetamine sulfate. ( Chan, S; Check, JH, 2014) |
| "To evaluate the efficacy of intratarsal triamcinolone acetonide (TA) injection versus dexamethasone ointment in the treatment of refractory chronic tropical endemic limboconjunctivitis (TELC)." | 5.16 | [Intratarsal triamcinolone acetonide injection for treatment of refractory chronic tropical endemic limboconjunctivitis (TELC): experience at Aristide-Le-Dantec university hospital in Dakar]. ( Ba, EH; Ka, AM; Ndiaye, MR; Ndoye Roth, PA; Ngatcho Hemo, J; Sow, AS; Wade, A; Wane Khouma, AM, 2012) |
| "Twenty-one patients with chronic schizophrenia who were hospitalized on a research ward received a single oral dose of dextroamphetamine (0." | 5.07 | Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. ( Bigelow, LB; Daniel, DG; Goldberg, TE; Kleinman, JE; Weinberger, DR, 1991) |
| "Dextroamphetamine sulfate 15-mg extended release capsules were given to women with a variety of treatment refractory conditions including, but not limited to, pelvic pain." | 3.81 | Sympathomimetic amines are a safe, highly effective therapy for several female chronic disorders that do not respond well to conventional therapy. ( Check, JH, 2015) |
| "To present two other dermatologic conditions related to a disorder of sympathetic nervous system hypofunction common in women that respond to treatment with dextroamphetamine sulfate--chronic eczema and keratosis pilaris." | 3.80 | Complete eradication of chronic long standing eczema and keratosis pilaris following treatment with dextroamphetamine sulfate. ( Chan, S; Check, JH, 2014) |
| "To determine if a very effective therapy for idiopathic orthostatic cyclic edema--dextroamphetamine sulfate--would alleviate symptoms of chonic pelvic pain of bladder origin/interstitial cystitis." | 3.73 | A novel highly effective treatment of interstitial cystitis causing chronic pelvic pain of bladder origin: case reports. ( Bonnes, E; Check, JH; Citerone, T; Katsoff, B, 2005) |
| " The medication trials were double-blind, placebo-controlled, dose-response studies." | 2.66 | Treatment of chronic closed head injury with psychostimulant drugs: a controlled case study and an appropriate evaluation procedure. ( Evans, RW; Gualtieri, CT; Patterson, D, 1987) |
| "Dextroamphetamine sulfate was initiated at 15 mg extended release capsules increasing to 25 mg extended release capsules to a 47-year-old woman." | 1.42 | Complete resolution of frozen shoulder syndrome in a woman treated with dextroamphetamine sulfate for chronic urinary urgency. ( Check, JH; Cohen, R, 2015) |
| "Dextroamphetamine sulfate was prescribed." | 1.40 | Sympathomimetic amine therapy found effective for treatment of refractory chronic complex regional pain syndrome (reflex sympathetic dystrophy). ( Check, JH; Cohen, R, 2014) |
| " Personal or family tic history, medication selection, or dosage was not related to onset of T/D." | 1.29 | Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. ( Adesman, AR; Goldstein, IJ; Lipkin, PH, 1994) |
| "The daytime somnolence was confirmed objectively by polygraphic monitoring seven weeks to 4 1/2 months after the onset of clinical symptoms." | 1.27 | Mononucleosis and chronic daytime sleepiness. A long-term follow-up study. ( Guilleminault, C; Mondini, S, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (37.50) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 8 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Check, JH | 8 |
| Chan, S | 1 |
| Cohen, R | 3 |
| Chiu, HF | 1 |
| Cheng, JK | 1 |
| Lin, PH | 1 |
| Chang, JC | 1 |
| Chen, IM | 1 |
| Lin, CI | 1 |
| Chang, WP | 1 |
| Lin, CH | 1 |
| Nuijten, M | 1 |
| Blanken, P | 1 |
| van de Wetering, B | 1 |
| Nuijen, B | 1 |
| van den Brink, W | 1 |
| Hendriks, VM | 1 |
| Check, D | 1 |
| Ndoye Roth, PA | 1 |
| Ngatcho Hemo, J | 1 |
| Wane Khouma, AM | 1 |
| Ba, EH | 1 |
| Sow, AS | 1 |
| Ka, AM | 1 |
| Ndiaye, MR | 1 |
| Wade, A | 1 |
| Katsoff, B | 1 |
| Citerone, T | 1 |
| Bonnes, E | 1 |
| Amadi, C | 1 |
| Kaplan, H | 1 |
| Katsoff, D | 1 |
| Whiting, E | 1 |
| Chenery, HJ | 1 |
| Chalk, J | 1 |
| Copland, DA | 1 |
| Gentlesk, MJ | 1 |
| Falanga, V | 1 |
| Wince, LC | 1 |
| Donovan, CA | 1 |
| Azzaro, AJ | 1 |
| Lipkin, PH | 1 |
| Goldstein, IJ | 1 |
| Adesman, AR | 1 |
| Gambarana, C | 1 |
| Masi, F | 1 |
| Tagliamonte, A | 1 |
| Scheggi, S | 1 |
| Ghiglieri, O | 1 |
| De Montis, MG | 1 |
| Vekovischeva, OY | 1 |
| Zamanillo, D | 1 |
| Echenko, O | 1 |
| Seppälä, T | 1 |
| Uusi-Oukari, M | 1 |
| Honkanen, A | 1 |
| Seeburg, PH | 1 |
| Sprengel, R | 1 |
| Korpi, ER | 1 |
| Goode, DJ | 1 |
| Meltzer, HY | 2 |
| Mazura, TA | 1 |
| Reches, A | 1 |
| Ebstein, RP | 1 |
| Belmaker, RH | 1 |
| Kornetsky, C | 1 |
| Goldberg, TE | 1 |
| Bigelow, LB | 1 |
| Weinberger, DR | 1 |
| Daniel, DG | 1 |
| Kleinman, JE | 1 |
| Sommers, AA | 1 |
| Luchins, DJ | 1 |
| Evans, RW | 1 |
| Gualtieri, CT | 1 |
| Patterson, D | 1 |
| Guilleminault, C | 1 |
| Mondini, S | 1 |
| Rappaport, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of 24 Weeks Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder With Comorbid Opioid Use Disorder - A Multicenter Randomized, Double-blind, Placebo-controlled Study[NCT05529927] | Phase 2 | 204 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | standardized T-score (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | % inhibition of startle (Mean) | |
|---|---|---|
| Placebo | Amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | msec (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
7 trials available for dextroamphetamine and Chronic Disease
| Article | Year |
|---|---|
Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Central Nervous System Stimulants; Chronic Disease; Cocaine-Related Disorders; | 2016 |
[Intratarsal triamcinolone acetonide injection for treatment of refractory chronic tropical endemic limboconjunctivitis (TELC): experience at Aristide-Le-Dantec university hospital in Dakar].
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Child; Child, Preschool; Chronic Disease; Conjunctiviti | 2012 |
Dexamphetamine boosts naming treatment effects in chronic aphasia.
Topics: Aged; Aphasia; Blood Pressure; Central Nervous System Stimulants; Chronic Disease; Dextroamphetamine | 2007 |
Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine.
Topics: Adult; Behavior; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Dextroamphetamine; Dopam | 1976 |
Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia.
Topics: Adult; Affect; Blinking; Cerebral Ventricles; Chronic Disease; Cognition; Concept Formation; Dextroa | 1991 |
The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
Topics: Alprazolam; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Dextroamphetamine; Dose | 1986 |
Treatment of chronic closed head injury with psychostimulant drugs: a controlled case study and an appropriate evaluation procedure.
Topics: Adult; Attention; Chronic Disease; Clinical Trials as Topic; Cognition Disorders; Craniocerebral Tra | 1987 |
17 other studies available for dextroamphetamine and Chronic Disease
| Article | Year |
|---|---|
Complete eradication of chronic long standing eczema and keratosis pilaris following treatment with dextroamphetamine sulfate.
Topics: Abnormalities, Multiple; Chronic Disease; Darier Disease; Dextroamphetamine; Eczema; Eyebrows; Fatig | 2014 |
Sympathomimetic amine therapy found effective for treatment of refractory chronic complex regional pain syndrome (reflex sympathetic dystrophy).
Topics: Acupuncture Analgesia; Adult; Central Nervous System Stimulants; Chronic Disease; Dextroamphetamine; | 2014 |
A mechanistic study on urine retention in d-amphetamine addicts.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Afferent Pathways; Amidines; Amphetamine-Related Disorders; An | 2014 |
Sympathomimetic amines are a safe, highly effective therapy for several female chronic disorders that do not respond well to conventional therapy.
Topics: Central Nervous System Stimulants; Chronic Disease; Cystitis, Interstitial; Dextroamphetamine; Fatig | 2015 |
Complete resolution of frozen shoulder syndrome in a woman treated with dextroamphetamine sulfate for chronic urinary urgency.
Topics: Bursitis; Chronic Disease; Dextroamphetamine; Female; Humans; Middle Aged; Sympathomimetics; Urinary | 2015 |
Idiopathic edema, a condition associated with pelvic pain and other symptoms in women, as a remedial cause of chronic cold induced urticaria.
Topics: Adolescent; Chronic Disease; Cold Temperature; Dextroamphetamine; Drug Resistance; Edema; Female; Hu | 2010 |
A novel highly effective treatment of interstitial cystitis causing chronic pelvic pain of bladder origin: case reports.
Topics: Adult; Chronic Disease; Cystitis, Interstitial; Dextroamphetamine; Female; Humans; Pelvic Pain; Symp | 2005 |
The treatment of idiopathic edema, a cause of chronic pelvic pain in women: effectively controlled chronic refractory urticaria--case reports.
Topics: Chronic Disease; Dextroamphetamine; Diagnosis, Differential; Edema; Female; Humans; Pelvic Pain; Ret | 2006 |
Sympathomimetic amines in the treatment of chronic urticaria: two case reports.
Topics: Adult; Chronic Disease; Dextroamphetamine; Edema; Female; Humans; Obesity; Posture; Urticaria | 1984 |
Alterations in the biochemical properties of central dopamine synapses following chronic postnatal PbCO3 exposure.
Topics: Animals; Brain; Chronic Disease; Dextroamphetamine; Dopamine; Lead Poisoning; Motor Activity; Potass | 1980 |
Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Chronic Disease; | 1994 |
A chronic stress that impairs reactivity in rats also decreases dopaminergic transmission in the nucleus accumbens: a microdialysis study.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Chronic Disease; Cocaine; Dextroamphetamine | 1999 |
Morphine-induced dependence and sensitization are altered in mice deficient in AMPA-type glutamate receptor-A subunits.
Topics: Acute Disease; Animals; Behavior, Animal; Brain; Calcium; Chronic Disease; Dextroamphetamine; Diseas | 2001 |
Hoffmann reflex abnormalities in psychotic patients.
Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Chronic Disease; Dextr | 1979 |
d-amphetamine inhibition of platelet MAO from schizophrenic patients.
Topics: Adult; Aged; Animals; Blood Platelets; Chronic Disease; Dextroamphetamine; Female; Haplorhini; Human | 1977 |
Mononucleosis and chronic daytime sleepiness. A long-term follow-up study.
Topics: Adolescent; Adult; Chronic Disease; Circadian Rhythm; Dextroamphetamine; Disorders of Excessive Somn | 1986 |
Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background.
Topics: Acute Disease; Adult; Attention; Auditory Perception; Chlorpromazine; Chronic Disease; Dextroampheta | 1968 |